Hepatology
The Hepatology Department at St James’s hospital, has a long established research program and runs a variety of both clinical trials and investigator led studies.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| ESSENCE | The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis | Clinical Trial (NCT04822181) | Novo Nordisk | Commercial: Industry |
| ZED 1227 | A phase IIb, double-blind, randomised, placebo-controlled, trial to evaluate the efficacy and tolerability of a 12-week treatment with ZED1277 capsules vs. placebo in celiac disease subjects experiencing symptoms despite gluten-free diet | Clinical Trial | Dr. Falk Pharma Gmbh | Commercial : Industry |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| NUT-3/NAS | Double-blind, randomised, placebo controlled, phase IIb clinical trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH) | Clinical Trial (2018-003443-31) | Dr Falk Pharma GmbH | Commercial: Industry |
| Intercept | A Phase 2, Double- Blind Randomized, Parallel- Group Study Evaluating the Efficacy, Safety and Tolerability of Obeticholic Acid, Administrated Alone or in Combination with Bezafibrate, in subjests with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid | Clinical trial | Intercept Pharmaceutials | Commercial: Industry |
| Abbvie M16-135 | A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1,2, 4, 5 or 6 Infection and Compensated Cirrhosis | Clinical Trial (NCT03089944) (2016-004967-38) | AbbVie | Commercial: Industry |
| NASH | A multi-centre, double blind placebo controlled, parallel randomised phase Iia study to investigate the safety, tolerability, pharmacodynamics & pharmacokinetics of different doses of orally administered BI 1467335 during a 12 week period compared to placebo in patients with clinical evidence of NASH | Clinical Trial (NCT03166735) (2016-000499-83) | Boehringer Ingeilheim | Commercial: Industry |
| HCV and Physical Activity | A determination of the relationship between physical activity, cardiovascular risk factors and metabolic profile in adults with Hepatitis C | Observational-non invasive | Non-commercial: Academic | |
| Intensive PK Study | Direct Acting Antivirals in Hepatitis C- Developing a personalized model of care: Intensive PK sub-study | Observational with radiology or blood tests | Non-commercial: Academic | |
| CANDI | Viral Hepatitis C Associated Neurocognitive Dysfunction in Ireland in the direct acting antiviral (DAA) era | Observational-non invasive | Non-commercial: Academic | |
| NAFLD Exercise Intervention | Non-alcoholic Fatty Liver Disease Exercise Intervention Protocol | Other | Non-commercial: Academic |